Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease

Kidney International

Volumn 91, Issue 3, 2017, Pages 711-719

  Munoz Mendoza, Jair ^a   Isakova, Tamara ^b   Cai, Xuan ^b   Bayes, Liz Y ^a   Faul, Christian ^a   Scialla, Julia J ^c,d   Lash, James P ^e,n   Chen, Jing ^f   He, Jiang ^f,n   Navaneethan, Sankar ^g,h   Negrea, Lavinia ⁱ   Rosas, Sylvia E ^j   Kretzler, Matthias ^k   Nessel, Lisa ^l   Xie, Dawei ^l   Anderson, Amanda Hyre ^l   Raj, Dominic S ^m   Wolf, Myles ^b   Appel, Lawrence J ⁿ   Feldman, Harold I ⁿ   Go, Alan S ⁿ   Kusek, John W ⁿ   Ojo, Akinlolu ⁿ   Townsend, Raymond R ⁿ   more..

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ILLINOIS   (United States)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m GEORGE WASHINGTON UNIVERSITY   (United States)

ⁿ NONE

more..

Author keywords

CKD; FGF23; inflammation; mortality

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 23; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; PHOSPHATE BINDING AGENT; STEROID; VITAMIN D; AUTACOID; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; C REACTIVE PROTEIN BLOOD LEVEL; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; END STAGE RENAL DISEASE; FEMALE; FIBROBLAST GROWTH FACTOR 23 BLOOD LEVEL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; INTERLEUKIN 6 BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; TIME FACTOR; UNITED STATES; UPREGULATION; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES; UP-REGULATION; YOUNG ADULT;

EID: 85010749584     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.10.021     Document Type: Article

References (58)

1. 1 Coresh, J., Selvin, E., Stevens, L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 (2007), 2038–2047.
2. 2 Go, A.S., Chertow, G.M., Fan, D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004), 1296–1305.
3. 3 Matsushita, K., van der Velde, M., Woodward, M., et al., for the Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375 (2010), 2073–2081.
4. 4 Wiggins, J.E., Patel, S.R., Shedden, K.A., et al. NFkappaB promotes inflammation, coagulation, and fibrosis in the aging glomerulus. J Am Soc Nephrol 21 (2010), 587–597.
5. 5 Coleman, D.L., Ruef, C., Interleukin-6: an autocrine regulator of mesangial cell growth. Kidney Int 41 (1992), 604–606.
6. 6 Navarro-Gonzalez, J.F., Mora-Fernandez, C., Muros de Fuentes, M., Garcia-Perez, J., Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7 (2011), 327–340.
7. 7 Clapp, B.R., Hingorani, A.D., Kharbanda, R.K., et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res 64 (2004), 172–178.
8. 8 Shoelson, S.E., Lee, J., Goldfine, A.B., Inflammation and insulin resistance. J Clin Invest 116 (2006), 1793–1801.
9. 9 Stemme, S., Faber, B., Holm, J., et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 92 (1995), 3893–3897.
10. 10 Hansson, G.K., Immune and inflammatory mechanisms in the development of atherosclerosis. Br Heart J 69:suppl 1 (1993), S38–S41.
11. 11 de la Mata, J., Uy, H.L., Guise, T.A., et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 95 (1995), 2846–2852.
12. 12 Nadra, I., Mason, J.C., Philippidis, P., et al. Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification?. Circ Res 96 (2005), 1248–1256.
13. 13 Gupta, J., Mitra, N., Kanetsky, P.A., et al., for the CRIC Study Investigators. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 7 (2012), 1938–1946.
14. 14 Shlipak, M.G., Fried, L.F., Crump, C., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107 (2003), 87–92.
15. 15 Gupta, J., Dominic, E.A., Fink, J.C., et al., for the CRIC Study Investigators. Association between inflammation and cardiac geometry in chronic kidney disease: findings from the CRIC Study. PLoS One, 10, 2015, e0124772.
16. 16 Chen, J., Mohler, E.R. 3rd, Xie, D., et al., for the CRIC Investigators. Risk factors for peripheral arterial disease among patients with chronic kidney disease. Am J Cardiol 110 (2012), 136–141.
17. 17 Stenvinkel, P., Heimburger, O., Paultre, F., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55 (1999), 1899–1911.
18. 18 Stenvinkel, P., Heimbürger, O., Jogestrand, T., Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 39 (2002), 274–282.
19. 19 Kato, A., Odamaki, M., Takita, T., et al. Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int 61 (2002), 1143–1152.
20. 20 Stompór, T., Pasowicz, M., Sułowicz, W., et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 41 (2003), 203–211.
21. 21 Amdur, R.L., Mukherjee, M., Go, A., et al., for the CRIC Study Investigators. Interleukin-6 is a risk factor for atrial fibrillation in chronic kidney disease: findings from the CRIC Study. PLoS One, 11, 2016, e0148189.
22. 22 Menon, V., Greene, T., Wang, X., et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 68 (2005), 766–772.
23. 23 Barreto, D.V., Barreto, F.C., Liabeuf, S., et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 77 (2010), 550–556.
24. 24 Gutierrez, O.M., Mannstadt, M., Isakova, T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359 (2008), 584–592.
25. 25 Isakova, T., Xie, H., Yang, W., et al., for the CRIC Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305 (2011), 2432–2439.
26. 26 Faul, C., Amaral, A.P., Oskouei, B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 121 (2011), 4393–4408.
27. 27 Gutierrez, O.M., Januzzi, J.L., Isakova, T., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119 (2009), 2545–2552.
28. 28 Scialla, J.J., Xie, H., Rahman, M., et al., for the CRIC Study Investigators. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 25 (2014), 349–360.
29. 29 Grabner, A., Amaral, A.P., Schramm, K., et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 22 (2015), 1020–1032.
30. 30 Munoz Mendoza, J., Isakova, T., Ricardo, A.C., et al. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 7 (2012), 1155–1162.
31. 31 David, V., Martin, A., Isakova, T., et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89 (2016), 135–146.
32. 32 Singh, S., Grabner, A., Yanucil, C., et al. Fiborblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 90 (2016), 985–996.
33. 33 Wilhelm-Leen, E.R., Hall, Y.N., Tamura, M.K., Chertow, G.M., Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey. Am J Med 122 (2009), 664–671.e2.
34. 34 Wanner, C., Zimmermann, J., Schwedler, S., Metzger, T., Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 80 (2002), 99–102.
35. 35 Honda, H., Qureshi, A.R., Heimburger, O., et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47 (2006), 139–148.
36. 36 Rao, M., Guo, D., Perianayagam, M.C., et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 45 (2005), 324–333.
37. 37 Nakamura, T., Miller, D., Ruoslahti, E., Border, W.A., Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1. Kidney Int 41 (1992), 1213–1221.
38. 38 Bertani, T., Abbate, M., Zoja, C., et al. Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 134 (1989), 419–430.
39. 39 Fattori, E., Della Rocca, C., Costa, P., et al. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood 83 (1994), 2570–2579.
40. 40 Bash, L.D., Erlinger, T.P., Coresh, J., et al. Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 53 (2009), 596–605.
41. 41 Fried, L., Solomon, C., Shlipak, M., et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 15 (2004), 3184–3191.
42. 42 Shankar, A., Sun, L., Klein, B.E., et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int 80 (2011), 1231–1238.
43. 43 Spoto, B., Mattace-Raso, F., Sijbrands, E., et al. Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD. Clin J Am Soc Nephrol 10 (2015), 232–240.
44. 44 Kendrick, J., Cheung, A.K., Kaufman, J.S., et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22 (2011), 1913–1922.
45. 45 Parker, B.D., Schurgers, L.J., Brandenburg, V.M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 152 (2010), 640–648.
46. 46 Manghat, P., Fraser, W.D., Wierzbicki, A.S., et al. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 21 (2010), 1853–1861.
47. 47 Ashikaga, E., Honda, H., Suzuki, H., et al. Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients. Ther Apher Dial 14 (2010), 315–322.
48. 48 Singh, R., Chennasamudram, S., Sheth, S., et al. Correlation of fibroblast growth factor 23 with markers of inflammation and endothelial dysfunction in end-stage renal disease and type 2 diabetes patients on peritoneal dialysis. J Diabetes Metab, 5, 2014, 2.
49. 49 Rossaint, J., Oehmichen, J., Van Aken, H., et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 126 (2016), 962–974.
50. 50 Chonchol, M., Greene, T., Zhang, Y., et al. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO Study. J Am Soc Nephrol 27 (2016), 227–237.
51. 51 Moreno, J.A., Izquierdo, M.C., Sanchez-Niño, M.D., et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol 22 (2011), 1315–1325.
52. 52 Hu, M.C., Shiizaki, K., Kuro-o, M., Moe, O.W., Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 75 (2013), 503–533.
53. 53 Navarro, J.F., Mora, C., Rivero, A., et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33 (1999), 458–463.
54. 54 Tuttle K, Adler S, Kretzler M. Baricitinib in diabetic kidney disease: results from a phase 2, multicenter, randomized, double-blind, placebo-controlled study. Paper presented at: the American Diabetes Association Meeting. June 5–9, 2015; Boston, MA.
55. 55 Feldman, H.I., Appel, L.J., Chertow, G.M., et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: design and methods. J Am Soc Nephrol 14:suppl 2 (2003), S148–S153.
56. 56 Fischer, M.J., Go, A.S., Lora, C.M., et al., CRIC and H-CRIC Study Groups. CKD in Hispanics: baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies. Am J Kidney Dis 58 (2011), 214–227.
57. 57 Levey, A.S., Stevens, L.A., Schmid, C.H., et al., for the CKD-EPI Collaboration. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
58. 58 Schaap, L.A., Pluijm, S.M., Deeg, D.J., Visser, M., Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 119 (2006), 526.e9–526.e17.